Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy
Introduction - Among antidotes in development for reversal of novel oral anticoagulants, dabigatran-specific idarucizumab was the first one to reach the market. Case presentation - We present the first Hungarian case of intracerebral hemorrhage under treatment with dabigatran, where idarucizumab was administered to suspend anticoagulation. Discussion - Our report is concordant with prior publications, confirming the efficacy of the antidote in reversing the effect of dabigatran, and thus, preventing intracerebral hematoma progression in the acute phase. Conclusion - Since there is no proven alternative to idarucizumab, conducting randomized clinical trials would be unethical. Therefore, besides case reports, positive results of prospective studies could help us revise therapeutic guidelines, and thus, improve the prognosis of dabigatran-associated intracerebral hemorrhages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Ideggyogyaszati szemle - 70(2017), 9-10 vom: 30. Sept., Seite 349-353 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Idarucizumab alkalmazása dabigatranterápia melletti spontán intracerebralis vérzésben |
|---|
| Beteiligte Personen: |
Bereczki, Dániel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
97RWB5S1U6 |
|---|
| Anmerkungen: |
Date Completed 24.01.2019 Date Revised 24.01.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18071/isz.70.0349 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28515575X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28515575X | ||
| 003 | DE-627 | ||
| 005 | 20231225044813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.18071/isz.70.0349 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0950.xml |
| 035 | |a (DE-627)NLM28515575X | ||
| 035 | |a (NLM)29870627 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Bereczki, Dániel |c Jr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy |
| 246 | 3 | 3 | |a Idarucizumab alkalmazása dabigatranterápia melletti spontán intracerebralis vérzésben |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2019 | ||
| 500 | |a Date Revised 24.01.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction - Among antidotes in development for reversal of novel oral anticoagulants, dabigatran-specific idarucizumab was the first one to reach the market. Case presentation - We present the first Hungarian case of intracerebral hemorrhage under treatment with dabigatran, where idarucizumab was administered to suspend anticoagulation. Discussion - Our report is concordant with prior publications, confirming the efficacy of the antidote in reversing the effect of dabigatran, and thus, preventing intracerebral hematoma progression in the acute phase. Conclusion - Since there is no proven alternative to idarucizumab, conducting randomized clinical trials would be unethical. Therefore, besides case reports, positive results of prospective studies could help us revise therapeutic guidelines, and thus, improve the prognosis of dabigatran-associated intracerebral hemorrhages | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a dabigatran | |
| 650 | 4 | |a idarucizumab | |
| 650 | 4 | |a intracerebral hemorrhage | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antidotes |2 NLM | |
| 650 | 7 | |a Antithrombins |2 NLM | |
| 650 | 7 | |a idarucizumab |2 NLM | |
| 650 | 7 | |a 97RWB5S1U6 |2 NLM | |
| 650 | 7 | |a Dabigatran |2 NLM | |
| 650 | 7 | |a I0VM4M70GC |2 NLM | |
| 700 | 1 | |a Szilágyi, Géza |e verfasserin |4 aut | |
| 700 | 1 | |a Kakuk, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Szakács, Zoltán |e verfasserin |4 aut | |
| 700 | 1 | |a May, Zsolt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ideggyogyaszati szemle |d 1954 |g 70(2017), 9-10 vom: 30. Sept., Seite 349-353 |w (DE-627)NLM119915138 |x 0019-1442 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2017 |g number:9-10 |g day:30 |g month:09 |g pages:349-353 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18071/isz.70.0349 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2017 |e 9-10 |b 30 |c 09 |h 349-353 | ||